Paclitaxel, an active agent in nonsquamous carcinomas of the uterine cervix: A Gynecologic Oncology Group Study

Purpose: A phase II trial of paclitaxel was initiated in advanced nonsquamo us carcinoma of the cervix to determine its activity in patients who had fa iled standard chemotherapy. Patients and Methods: Eligible patients had at least one measurable lesion. The starting dose of paclitaxel was 170 mg/m(2) (135 mg/m(2) for patients with prior pelvic radiation) given as a 24-hour continuous intravenous infu sion with courses repeated every 3 weeks, Dose escalation to 200 mg/m(2) an d de-escalation to 110 mg/m(2) were allowed based on adverse effects. Results: In this trial, 42 assessable patients were initially entered onto the study, and 13 responses were seen; four patients had a complete respons e, and nine patients had a partial response. The overall response rate was 31%. The primary and dose-limiting toxicity was neutropenia. Conclusion: The response rate to paclitaxel exceeds the rates reported usin g other single agents in nonsquamous carcinoma of the cervix. J Clin Oncol 19:1275-1278. (C) 2001 by American Society of Clinical Oncology.